Loading stock data…
Tango Therapeutics (TNGX)
$22.70+0.18 (+0.80%)
Market ClosedLast close Sep 8
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Tango Therapeutics, Inc. in the Healthcare sector is trading at $22.70 with a market capitalization of $5.3B. Wall Street consensus targets $45.18 (11 analysts), implying a +99.0% move over the next 12 months. The stock is currently 34% below its 52-week high of $34.39, remaining 15.4% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +99.0% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Oversold momentum (RSI 33) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0↓ | $53.81M↑ | $3.18M↓ | $5.39M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$48.77M↓ | -$41.86M↓ | $14.07M↑ | -$40.97M↑ | -$42.53M |
| Net Income | -$45.51M↓ | -$38.75M↓ | $15.88M↑ | -$38.85M↑ | -$39.88M |
Peer Comparison
JNJUNHPFE
Fundamentals
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$5.31B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-27.39%
Volume
Today's trading volume
2.42M
Recent News
Tango Therapeutics (TNGX) At 3.7x P B As Pullback Tests Whether It Looks Pricey
Tango Therapeutics stock reaction and recent performance Tango Therapeutics (TNGX) has drawn investor attention after recent trading moves, with the stock closing at US$22.76 on the latest trading day. The price change offers a fresh prompt to reassess the company’s recent performance. Over the past month, Tango Therapeutics stock has fallen about 22%, while the past 3 months show a gain of roughly 13%. Year to date, the stock return is about 155%, and the 1-year total return is about...
TNGX Stock Dips 5% as Q2 Earnings Miss Estimates on Higher Expenses
Tango Therapeutics stock falls 5% on a wider-than-expected Q2 loss, reflecting higher operating expenses, while pipeline progress remains in focus.
How Much Upside is Left in Tango Therapeutics (TNGX)? Wall Street Analysts Think 49.48%
The average of price targets set by Wall Street analysts indicates a potential upside of 49.5% in Tango Therapeutics (TNGX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Tango Therapeutics (TNGX) to Benefit From Vopimetostat + KRAS Inhibitors Combined Revenues
Tango Therapeutics Inc. (NASDAQ:TNGX) is one of the 10 affordable biotech stocks to buy right now. On June 29, Canaccord Genuity increased its target price on Tango Therapeutics Inc. (NASDAQ:TNGX) from $42 to $46, resulting in more than 53% upside potential. The firm kept a Buy rating on the stock, highlighting further upside from vopimetostat + […]
2 Monster Growth Stocks Analysts Think Can Reach New Highs
There’s no shortage of investing strategies, but growth investing remains one of the most popular approaches. Stocks that climb 50%, 100%, or more over a relatively short period rarely do so by chance. In many cases, the move is driven by improving fundamentals, a successful new product, expanding demand, or another development that changes how the market views the business. Of course, a rising share price alone is never enough to justify an investment. Past performance does not guarantee future